Concepedia
Statistics
Publications
22
Citations
3.1K
H-Index
20
Active since
1982
Affiliations
Regeneron (United States)(Current)
University of Southern California
Novo Nordisk (Denmark)
University of Illinois Urbana-Champaign
Joel Martin is an author at Regeneron (United States) specializing in life sciences, medicine, and pharmacology.
Publications per year
1982–2020
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos, Joel Martin, Qin Ruan et al. · Angiogenesis · 2012 · 1K citations · Full text
Medicine, Oncology, Pharmacology +15
Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
Audrey Le Floc’h, Jeanne Allinne, Kirsten Nagashima et al. · Allergy · 2019 · 490 citations · Full text
Medicine, Immunology, Pharmacology +17
p493F12 kinase: A novel MAP kinase expressed in a subset of neurons in the human nervous system
Abdi A. Mohit, Joel Martin, Carol A. Miller · Neuron · 1995 · 208 citations
Life Sciences, Neurobiology, Neuroscience +11
Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates
Kristen E. Pascal, Drew Dudgeon, John C. Trefry et al. · The Journal of Infectious Diseases · 2018 · 186 citations · Full text
Pharmacy, Infectious Diseases, Pharmacology +17
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
Dimitris Skokos, Janelle Waite, Lauric Haber et al. · Science Translational Medicine · 2020 · 153 citations
Life Sciences, Immunology, Oncology +16
1–5 of 22